Education
About Us
Working with TipRanks
Follow Us
Silexion Therapeutics Corp (SLXN)
:SLXN
SLXN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.58 - $122.01
Previous CloseN/A
Volume52.80K
Average Volume (3M)24.52M
Market Cap
$9.00M
Enterprise ValueN/A
Total Cash (Recent Filing)$4.59M
Total Debt (Recent Filing)$171.00K
Price to Earnings (P/E)―
Beta-0.78
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.70
Shares Outstanding8,414,615
10 Day Avg. Volume9,766,186
30 Day Avg. Volume24,517,544
Standard Deviation0.28
R-Squared0.27
Alpha-0.34
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.00Price Target Upside741.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Silexion Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Market OpportunityPositive pre-clinical results of systemic administration of SIL-204 in pancreatic cancer models could allow Silexion to target both metastatic pancreatic cancer and locally advanced pancreatic cancer, materially increasing the market opportunity.
Partnership And TechnologySilexion announced they have been partnered with Evonik, a leading German specialty chemicals company, to develop SIL-204.
Bears Say
Financial PositionSilexion ended the period with $2.0M in cash and equivalents, and additional capital will likely be required by year-end for conducting manufacturing work and the next clinical studies.
---
Ownership Overview
―
Insiders
0.33% Mutual Funds
1.35% Other Institutional Investors
98.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
SLXN FAQ
What was Silexion Therapeutics Corp’s price range in the past 12 months?
Silexion Therapeutics Corp lowest stock price was $0.57 and its highest was $122.01 in the past 12 months.
What is Silexion Therapeutics Corp’s market cap?
Silexion Therapeutics Corp’s market cap is $9.00M.
When is Silexion Therapeutics Corp’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Silexion Therapeutics Corp’s earnings last quarter?
Currently, no data Available
Is Silexion Therapeutics Corp overvalued?
According to Wall Street analysts Silexion Therapeutics Corp’s price is currently Undervalued.
Does Silexion Therapeutics Corp pay dividends?
Silexion Therapeutics Corp does not currently pay dividends.
What is Silexion Therapeutics Corp’s EPS estimate?
Silexion Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Silexion Therapeutics Corp have?
Silexion Therapeutics Corp has 8,414,615 shares outstanding.
What happened to Silexion Therapeutics Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Silexion Therapeutics Corp?
Currently, no hedge funds are holding shares in SLXN
---
Company Description
Silexion Therapeutics Corp
Moringa Acquisition Corp is a blank check company.
---
SLXN Stock 12 Month Forecast
Average Price Target
$9.00
▲(741.12% Upside)
Technical Analysis
Best Analysts Covering SLXN
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-59.93%
reiterated a buy rating last month
Copying Naz Rahman's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -59.93% per trade.
---